FDA Clears Regulus Therapeutics’ IND for RGLS8429 In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (NASDAQ: RGLS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Allarity Therapeutics (NASDAQ:ALLR) stock rose 25.3% to $2.84 during Monday's after-market session. The market value of their outstanding shares is at $22.9 million.
Regulus Therapeutics’s Earnings: A Preview
Regulus Therapeutics (NASDAQ:RGLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.
Analysts estimate that Regulus Therapeutics will report an earnings per share (EPS) of $-0.07.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
68 Biggest Movers From Yesterday
Gainers
ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder
Regulus Therapeutics Inc (NASDAQ: RGLS) has